核团特异性额叶-杏仁核通路及其神经递质受体分布:对抗抑郁药选择的启示
研究基于106例MDD患者的弥散张量成像,用概率 tractography 估计皮质-杏仁核白质连接,K-modes聚类按皮质投射划分杏仁核亚区,比较SSRI与SNRI改善者的FA值。发现额叶与内侧杏仁核核团间白质连接差异对应药理倾向模式,与5-羟色胺和去甲肾上腺素系统一致,并介导SLC6A4遗传风险对治疗倾向的影响,在66例独立队列中验证。
要点
- 额叶-内侧杏仁核白质连接FA差异可区分SSRI与SNRI改善者。
- 该连接模式与5-羟色胺/去甲肾上腺素系统呈组特异性对齐。
- 该模式介导SLC6A4遗传风险对治疗倾向的影响,并在独立队列验证。
核心结论
- 额叶与内侧杏仁核核团间白质连接差异对应抗抑郁药药理倾向模式,为MDD治疗决策提供可检验证据。
研究设计与样本
- 发现队列纳入106例对SSRI或SNRI应答的MDD患者,基于弥散张量成像用概率 tractography 估计皮质-杏仁核白质连接。
- 用K-modes聚类按皮质投射将杏仁核划分为亚区,比较各皮质-亚区白质连接FA值。
- 对区分性白质连接进行微尺度转录组与化学架构解码,并在66例MDD独立验证队列中通过靶向SNP基因分型验证。
主要发现
- 识别出额叶与内侧杏仁核核团间白质连接的关键差异,对应药理倾向模式。
- 该模式以组特异性方式与5-羟色胺和去甲肾上腺素神经递质系统对齐。
- 该模式介导SLC6A4遗传风险对治疗倾向的影响。
临床怎么用
- 核团水平皮质-杏仁核白质连接结合神经递质受体分布与遗传变异,可为MDD抗抑郁药选择提供参考信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The amygdala and its cortical connections play an important role in antidepressant treatment of major depressive disorder (MDD). While it can be subdivided according to its cortical connections, the anatomical and molecular heterogeneity across these subdivisions in MDD patients responding to different antidepressants remain unclear. Therefore, we aimed to investigate whether nuclei-level cortico-amygdala white matter (WM) connectivity differentiates responses to two first-line treatments - selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI); and to clarify the molecular underpinnings of such difference. From diffusion tensor imaging data in a discovery cohort of 106 MDD patients who response to SSRI (SSRI-Improvers) or SNRI (SNRI-Improvers), cortico-amygdala WM connectivity was estimated via probabilistic tractography. K-modes clustering was applied to cluster the amygdala into subdivisions by cortical projections. Fractional anisotropy (FA) values of each cortico-subdivision WM connection were then compared between SSRI-Improvers and SNRI-Improvers. Finally, the discriminative WM connection was decoded using microscale transcriptomic and chemo-architecture analysis, and its relevance was validated in an independent replication cohort of 66 MDD patients through targeted single-nucleotide polymorphisms (SNP) genotyping. A key difference in WM connection between frontal lobe and medial amygdala nucleus (medialAMY) was identified, which refers to a pharmacological propensity pattern. Such pattern was aligned with the serotonin and noradrenaline neurotransmitter system in a group-specific manner, and mediated the effects of genetic risks of SLC6A4 on treatment inclination. The convergence of macroscale pharmacological propensity connectome, microscale molecular architecture, and genetic variation provides new testable evidence to inform decision-making in antidepressant treatment of MDD.
引用
- Xue L, Wang T, Shao J, et al. A nuclei-specific fronto-amygdala pathway and its neurotransmitter receptor distribution: Implications for Antidepressant Selection. Mol Psychiatry. 2026. PMID: 41748920. doi:10.1038/s41380-026-03502-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。